Wainzua
Named-patient access overview. Wainzua is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Wainzua
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Wainua (eplontersen) is the GalNAc-conjugated antisense oligonucleotide for hereditary transthyretin-mediated amyloidosis with polyneuropathy. It received FDA approval in December 2023 and is co-commercialized in the US under the Wainua brand by Ionis Pharmaceuticals and AstraZeneca; the underlying brand attribution in your home jurisdiction may use either name. For Saudi Arabia patients with confirmed hATTR-PN whose treating physician has recommended eplontersen, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Wainzua
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Wainzua is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Wainzua in every market we coordinate. Each page below covers the destination-country regulatory pathway, how quotes work, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Wainzua
Submit a 60-second intake. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Wainzua if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Wainzua for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Wainzua through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Wainzua. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Wainzua through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Wainzua to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Wainzua to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Wainzua cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Wainzua?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.